Myriad Genetics, Inc. MYGN
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -43.90M | -43.20M | -34.10M | -7.90M | -27.40M |
| Total Depreciation and Amortization | 12.60M | 12.50M | 12.50M | 12.60M | 12.60M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.20M | 9.00M | 14.10M | 7.50M | 14.50M |
| Change in Net Operating Assets | 13.60M | 13.40M | -8.20M | -1.60M | 21.40M |
| Cash from Operations | -6.50M | -8.30M | -15.70M | 10.60M | 21.10M |
| Capital Expenditure | -1.80M | -2.10M | -5.40M | -4.70M | -2.80M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -300.00K | -1.10M | -1.10M | -1.30M | -3.40M |
| Cash from Investing | -2.10M | -3.20M | -6.50M | -6.00M | -6.20M |
| Total Debt Issued | -- | -- | -- | 0.00 | 125.00M |
| Total Debt Repaid | -100.00K | -200.00K | -100.00K | 300.00K | -60.10M |
| Issuance of Common Stock | 0.00 | 2.80M | -- | 600.00K | 0.00 |
| Repurchase of Common Stock | -200.00K | -400.00K | -2.90M | -1.20M | -300.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -7.90M | -8.40M |
| Cash from Financing | -300.00K | 2.20M | -3.00M | -8.20M | 56.20M |
| Foreign Exchange rate Adjustments | -100.00K | 100.00K | -100.00K | 100.00K | 0.00 |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -9.00M | -9.20M | -25.30M | -3.50M | 71.10M |